InvestorsHub Logo
Followers 155
Posts 2647
Boards Moderated 0
Alias Born 01/29/2004

Re: jimmy667 post# 107624

Thursday, 06/08/2017 10:57:16 AM

Thursday, June 08, 2017 10:57:16 AM

Post# of 462630
Well said. The science not a factor.

Those of us who have studied and understand the revolutionary new biochemistry of the Anavex molecules, and how they will revolutionize 21st-century even more than antibiotics did in the last century continue to ponder the continuing ridiculously low share price range of AVXL. What's the deal?

It's clearly this. For retail stock buyers, the unique biochemistry is some pretty complicated "brain science," understood only by brain scientists; beyond the man on the street trying to conduct due diligence.

Institutional buyers, hedge funds, mutual funds, and the like also discount or fail to understand the science. Lots and lots of science for lots and lots of both new and old pharmaceutical companies. Pure science never elevates share prices. Only FDA drug approvals and consequent drug sales do that. Institutional buyers look only for information telling of such regulatory and sales developments. The science be damned. The ability to profitably sell shares and drugs are the only controlling factors being assessed.

So, until Missling or the company can tell some news related to future sales --- such as positive Rett or Alzheimer's trial results --- AVXL share prices will continue to trade in a narrow range; perhaps even trending downward. Projected and anticipated $$$ will be in control, not understandings or applications of the authentic underlying science.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News